



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HANAA ALY



Evaluation of miRNA-106a and ADARB1 in Autistic Children

Thesis

*Submitted for Partial Fulfillment of Master Degree in
Medical Biochemistry & Molecular Biology*

By

Brihan Magdy Abdu-Allah Zamil

Demonstrator of Medical Biochemistry and Molecular Biology

M.B.B.Ch.,

Faculty of Medicine - Ain Shams University

Under supervision of

Prof. Dr. Randa Ali-Labib

Professor of Medical Biochemistry and Molecular Biology

Faculty of Medicine, Ain Shams University

Dr. Eman Khairy Farahat

Assistant Professor of Medical Biochemistry and Molecular Biology

Faculty of Medicine, Ain Shams University

Dr. Walaa Youssef Youssef

Lecturer of Pediatrics

Faculty of Medicine, Ain Shams University

*Faculty of Medicine
Ain Shams University*

2020

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببنا أنك لا تعلم لنا
إلا ما علمتنا أنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**,
the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Randa Ali-Labib**, Professor of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Ain Shams University for her keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Dr. Eman Khairy Farahat**, Assistant Professor of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr. Walaa Youssef Youssef**, Lecturer of Pediatrics, Faculty of Medicine, Ain Shams University, for her great help, active participation and guidance.*

Finally, all my sincerest thanks to my husband, my beautiful daughter and my family for their care, support and encouragement, and my friends and colleagues for their valuable help and advice.

Brihan Magdy

List of Contents

Title	Page No.
List of Tables	i
List of Figures	ii
List of Abbreviations.....	iii
Introduction	1
Aim of the Work.....	4
Review of Literature	
Autism Spectrum Disorder.....	5
MicroRNA.....	17
ADARB1	28
Subjects and Methods.....	35
Results	56
Discussion	76
Summary, Conclusion and Recommendations	93
References	96
Arabic Summary	—

List of Tables

Table No.	Title	Page No.
Table (1):	The association of the quantitative characteristics in the different study groups.	57
Table (2):	Percentage of risk factors in different study groups.	58
Table (3):	Relative Expression of miR-106a and ADARB1 in autistic children and control group.	60
Table (4):	The relation between CARS score and studied biomarkers in autistic cases.	65
Table (5):	miR-106a serum expression level in relation to different variables among children with Autism.	67
Table (6):	miR-106a serum expression level in relation to specific clinical characteristics among children with Autism.	68
Table (7):	ADARB1 mRNA serum level in relation to different studied variables among children with Autism.	69
Table (8):	ADARB1 serum expression level in relation to specific clinical characteristics among children with Autism.	70
Table (9):	Correlation between serum miR-106a level with different variables in studied groups.	71
Table (10):	Correlation between serum ADARB1 level with different variables in studied groups.	72
Table (11):	Correlation between assessed biomarkers and variable scores in autistic cases.	74
Table (12):	Correlation between serum level of miR-106a and ADARB1 mRNA in the studied groups.	75

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Vineland Adaptive Behavior Scales domains and subdomains.....	10
Figure (2):	Canonical and mirtron noncanonical pathway biogenesis of miRNA	21
Figure (3):	ADARs catalyse hydrolytic deamination of adenosines to inosines which are similar to guanosines	29
Figure (4):	Editing sites in the glutamate receptors pre mRNA.....	31
Figure (5):	Editing sites in serotonin receptor pre mRNA	32
Figure (6):	Snapshot shows the involvement of miR-106a in Autism spectrum disorder.....	37
Figure (7):	Snapshot shows ADARB1 gene is one of the predicting targets to miR-106a.....	38
Figure (8):	Snapshot shows miR-106a/ADARB1 alignment.....	39
Figure (9):	Box plot showing the median value and range of the serum miR-106a level in both groups.	61
Figure (10):	Box plot showing the median value and range of the serum ADARB1 mRNA level in both groups.	61
Figure (11):	(ROC) Curve analysis and cutoff value for serum MiR-106a level.	63
Figure (12):	(ROC) Curve analysis and cutoff value for serum ADARB1 mRNA level.	64

List of Abbreviations

Abb.	Full term
A.....	Adenosine
ABC	Adaptive Behavior Composite score
ADARB1	Adenosine Deaminase Acting on RNA B1
ADHD	Attention deficit/hyperactivity disorder
Ads.....	Autoimmune diseases
AGO	Argonaute family proteins
APP	Amyloid precursor protein
ASD.....	Autism spectrum disorder
AUC	Area under the curve
BBB	Blood - brain barrier
Ca.....	Calcium
CARS	Childhood Autism Rating Scale
cDNA	Complementary DNA
CELF	CUG-BP, Elav-like family
CMPs	Chromatin modifiers proteins
CNS	Central nervous system
CRH	Corticotropin-releasing hormone
CSF	Cerebrospinal fluid
Ct	Threshold Cycle
DGCR8	DiGeorge syndrome critical region gene 8
DM	Deaminase domain
dsRBDs.....	Double stranded RNA binding domains
dsRBPs	Double stranded RNA-binding proteins
DUI.....	daytime urinary incontinence
FN	False negatives
FP	False positives
FR	Folate receptor
G	Guanosine
GIT.....	Gastrointestinal tract

List of Abbreviations Cont...

Abb.	Full term
GluRs.....	Glutamate receptors
GSH	Glutathione
GSH-PX.....	Glutathione peroxidase
GW182.....	Glycine-tryptophan protein of 182 kDa
HDL	High density lipoprotein
HMDD V2	Human microRNA Disease Database, version 2
HT2C	Serotonin
I.....	Inosine
I/V	Isoleucine to valine
ICU	Intensive care unit
ID.....	Intellectual disability
IL	Interleukin
Imp8	Importin 8
IP6	Inositol hexakisphosphate
IQ.....	Intelligent quotient assessment
LBW.....	Low birth weight
lincRNAs	Large intergenic non-coding RNAs
lncRNAs.....	Long non-coding RNAs
MDD	Major depressive disorder
MECP2	Methyl CpG binding protein 2
MHC	Major histocompatibility complex
miRNAs	Micro RNAs
MREs	miRNA response elements
mRNA.....	Messenger RNA
MTHF	5-methylene tetra hydrofolate
MTHFR	Methylene tetra hydrofolate reductase
n.....	Number
NE.....	nocturnal enuresis
NICU	Neonatal intensive care unit

List of Abbreviations Cont...

Abb.	Full term
NLGN	Neuroligins
NMDAR.....	N-methyl-D-aspartate receptor
NPV	Negative predictive value
NRXN	Neurexin
nt.....	Nucleotides
OMSCs	Olfactory mucosal stem cells
PACT	Protein activator of the interferon-induced protein kinase
PAHs.....	Polycyclic aromatic hydrocarbons
PCR.....	Polymerase chain reaction`
piRNAs	PIWI-interacting RNAs
Pol II.....	Polymerase II
PPV.....	Positive predictive value
pre-miRNA	Precursor miRNA
pri-miRNA.....	Primary transcript
PTBP1/2	polypyrimidine tract binding protein 1 and 2
Q/R.....	Glutamine to arginine
qRT-PCR	Quantitative reverse transcription polymerase chain reaction
r.....	Correlation coefficient
R/G.....	Arginine to glycine
RA.....	Rheumatoid arthritis
RISC	RNA-induced silencing complex
ROC	Receiver operating characteristic
RQ.....	Relative quantity
rRNAs.....	Ribosomal RNAs
SD	Standard deviation
SHANK.....	SH3 and multiple ankyrin repeat domains
shRNAs.....	Short hairpin RNAs

List of Abbreviations Cont...

Abb.	Full term
siRNAs.....	Small interfering RNAs
SLE.....	Systemic lupus erythematosus
snoRNAs.....	Nucleolar RNAs
SNPs.....	Single nucleotide polymorphisms
snRNAs.....	Small nuclear RNAs
SOD	Super oxide dismutase
SPSS.....	Statistical Package for Social Sciences
stRNAs	Small temporal RNAs
TAR.....	Transactivation-responsive
TE	Tris-EDTA
TGA	Transcriptional gene activation
TGS.....	Transcriptional gene silencing
TN.....	True negatives
TNF	Tumor necrosis factor
TP	True positives
TRBP	Transactivation-responsive RNA-binding proteins
tRNAs.....	Transfer RNAs
T-UCRs.....	Transcribed ultra-conserved regions
UTR	Untranslated region
VABS	Vineland Adaptive Behavior Scales
X.....	Mean
Y/C	Tyrosine to cysteine
Δ Ct.....	Delta Threshold Cycle
°C	Centigrade

INTRODUCTION

Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized by disturbances in social interactions, language, and communication, as well as by the presence of stereotyped behaviors and restricted interests (*Salem et al., 2013*).

In most cases, ASD symptoms are first recognized in early childhood. The average age of ASD diagnosis is 4 years. The world Health Organization estimated the prevalence of ASD in children to be 1 in 160 worldwide (*World Health Organization, 2018*). This increased prevalence will have enormous future public health implications, and has necessitated the need to discover predictive noninvasive biomarkers that could be index for autism before the onset of symptoms (*Anitha and Thanseem, 2015*).

In recent years, epigenetic mechanisms, which act at the interface of genes and the environment, have been identified as a potential contributor to the pathogenesis of several neurodevelopmental abnormalities such as ASD. Epigenetic factors control heritable changes in gene expression without changing the DNA sequence. MicroRNAs (miRNAs) have recently emerged as prominent epigenetic regulators of a variety of cellular processes, including differentiation, apoptosis and metabolism (*Vasu et al., 2014*).

MicroRNAs (miRNAs) are small RNA molecules of approximately 22 nucleotides that regulate the expression of genes by binding to the 3'untranslated regions (3'UTR) of specific mRNAs directing translational repression or transcript degradation (*Talebizadeh et al., 2008*). MiRNAs are abundantly present in brain (*Vasu et al., 2014*), and have been found to play important roles in neurogenesis, synaptogenesis, and neuronal migration (*Hicks et al., 2016*).

Abnormal expression of circulating miRNAs have been reported in several neurological and neurodevelopmental disorders. Thus, miRNAs within the central nervous system (CNS) may be exported across the blood–brain barrier (BBB) by the microvesicles (exosomes) released by neurons and glial cells (*Anitha and Thanseem, 2015*). Serum miRNAs, which may be derived from circulating blood cells, are known to be stable and resistant to the action of RNase, suggesting the potential efficacy of serum miRNAs as noninvasive biomarkers for ASD (*Vasu et al., 2014*).

Based on using HMDD V2 (the Human microRNA Disease Database, version 2) and PhenomiR database, and according to *Abu-Elneel et al. (2008)*, miRNA-106a has been reported to be differentially expressed in postmortem cerebellar cortex tissue of individuals with ASD compared to non ASD individuals. This miRNA was also deregulated in serum of astrocytoma patients, a primary brain tumor, and in whole blood samples of Alzheimer's disease as reported by *Zhi et al,*